Stanford trial points to a new CAR-T drug, spotlighting a fresh target for next-gen cell therapies
CAR-T researchers have had years to study CD19 protein molecules as a target in their successful leukemia studies. But a small, exploratory study at Stanford underscores that there’s substantial promise in expanding their scope to include CD22, offering a new route to follow for patients who relapse — or never respond — after being treated with the first round of cell therapies now hitting the market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
